Sciarra Alessandro, Gentilucci Alessandro, Salciccia Stefano, Pierella Federico, Del Bianco Flavio, Gentile Vincenzo, Silvestri Ida, Cattarino Susanna
Department of Urology, University Sapienza of Rome, Rome, Italy ; Department of Urological science, University Sapienza, Viale Policlinico 155, 00161 Rome, Italy.
Department of Urology, University Sapienza of Rome, Rome, Italy.
J Inflamm (Lond). 2016 Nov 25;13:35. doi: 10.1186/s12950-016-0143-2. eCollection 2016.
Prostate is an immune-competent organ normally populated by inflammatory cells. Prostatic inflammation origin can be multi-factorial and there are some emerging evidences on its possible role as a factor involved in prostate cancer (PC) pathogenesis and progression. This review critically analyzes the role of inflammation as a prognostic factor for progression and aggressiveness of PC. We verified the last 10 years literature data on the association between inflammation and PC aggressiveness, or PC response to therapies. Several studies tried to correlate different inflammatory factors with the aggressiveness and metastatization of PC; all data sustain the role of inflammation in PC progression but they also produce confusion to identify a reliable clinical prognostic marker. Data on patients submitted to radical prostatectomy (RP) showed that cases with marked intraprostatic tissue inflammation are associated with higher rate of biochemical progression; systemic inflammation markers appear to have a significant prognostic value. Analyzing data on patients submitted to radiotherapy (RT) emerges a significant association between high neuthrophil to lymphocyte ratio (NLR) and decreased progression free survival and overall survival; also plateled to lymphocyte ratio (PLR) and C-reactive protein (CRP) have been proposed as significant prognostic factors for progression and overall survival. In patients submitted to androgen deprivation therapy (ADT), inflammation may drive castration resistant PC (CRPC) development by activation of STAT3 in PC cells. NLR has been proposed as independent predictor of overall survival in CRPC submitted to chemotherapy. Most of data are focused on markers related to systemic inflammation such as NLR and CRP, more than specifically to chronic prostatic inflammation. The suggestion is that these inflammatory parameters, also if not specific for prostatic inflammation and possibly influenced by several factors other than PC, can integrate with established prognostic factors.
前列腺是一个通常有炎症细胞浸润的具有免疫活性的器官。前列腺炎症的起源可能是多因素的,并且有一些新证据表明其可能作为前列腺癌(PC)发病机制和进展中的一个因素发挥作用。本综述批判性地分析了炎症作为PC进展和侵袭性的预后因素的作用。我们核实了过去10年关于炎症与PC侵袭性或PC对治疗反应之间关联的文献数据。多项研究试图将不同的炎症因子与PC的侵袭性和转移相关联;所有数据都支持炎症在PC进展中的作用,但它们也在确定可靠的临床预后标志物方面产生了混淆。接受根治性前列腺切除术(RP)的患者的数据显示,前列腺组织内有明显炎症的病例与更高的生化进展率相关;全身炎症标志物似乎具有显著的预后价值。分析接受放疗(RT)的患者的数据发现,高中性粒细胞与淋巴细胞比率(NLR)与无进展生存期和总生存期降低之间存在显著关联;血小板与淋巴细胞比率(PLR)和C反应蛋白(CRP)也被提议作为进展和总生存期的重要预后因素。在接受雄激素剥夺治疗(ADT)的患者中,炎症可能通过激活PC细胞中的STAT3来驱动去势抵抗性PC(CRPC)的发展。NLR已被提议作为接受化疗的CRPC患者总生存期的独立预测指标。大多数数据集中在与全身炎症相关的标志物,如NLR和CRP上,而不是特别针对慢性前列腺炎症。这些炎症参数的建议是,即使它们并非前列腺炎症所特有,并且可能受到PC以外的多种因素影响,但它们仍可与已确立的预后因素相结合。